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ity of these tumors are squamous cell carcinoma (HNSCC). With a stable overall survival rate of
50% among all stages, there is continued interested in developing measures for early detection
and disease aggressiveness. Circulating tumor cells (CTCs) have been identified as a potential
marker for early metastatic disease, response to treatment, and surveillance in head and neck
squamous cell carcinoma. In this article, techniques of CTC detection, applications of CTC
technology, and outcomes of HNSCC patients will be discussed.
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Cancer of the upper aerodigestive system comprised an
estimated 59,340 cases in the United States in 2015 and
3.5% of all cancers,1 with squamous cell carcinoma of the
head and neck (HNSCC) making up approximately 95% of
these tumors. The overall 5-year survival for all stages
combined is approximately 50%, and this overall figure has
not changed much in the past few decades. Although there
have been advances in disease stratification according to
site (HPV association with improved survival innd hosting by Elsevier B.V. on behalf of KeAi Communications Co.,
://creativecommons.org/licenses/by-nc-nd/4.0/).
110 K.P. McMullen et al.oropharyngeal carcinoma2,3), there is a relative paucity of
information with regards to predicting outcome in HPV
negative oropharyngeal tumors and those from other aer-
odigestive sites. Presence of lymphatic metastases is a main
indicator of poor prognosis; however, microscopic metas-
tases to lymph nodes occur in 11%e50% of head and neck
tumors, depending on site.4e6 Metastases develop when
tumor cells acquire properties to invade the local lymphatic
and vascular spaces, migrate into the bloodstream or
lymphatic system, and then develop the ability to prolif-
erate in lymph nodes and distant sites. The capacity to
measure tumor cells circulating through the vasculature
provide definitive evidence of the aggressiveness of a tumor
prior to detection of identifiable metastases. If a blood test
existed, this may improve the ability to stratify patients for
a particular treatment. Circulating tumor cells (CTCs) have
been identified as a marker for disease severity in other
fields, with poor outcomes in breast,7 colorectal,8,9 and
prostate cancer,10,11 among others. In head and neck
oncology, identification of circulating tumor cells in pa-
tients with squamous cell carcinoma may be a promising
tool toward development of a “liquid biopsy” for disease
severity, providing early and definitive evidence of meta-
static disease. Detection of CTCs may also provide oppor-
tunities for targeted treatment through genetic analysis,
aid in response to treatment, and serve as a marker for
post-treatment surveillance. Over the past twenty years,
there have been significant advances in the field of circu-
lating tumor cells in SCCHN.CTC detection methods
Detecting CTCs in peripheral blood is a challenge by virtue of
the seven to eight order of magnitude difference in the
number of normal circulating blood cells and abnormal tumor
cells in circulation. In each milliliter of whole blood, there
are approximately 5 billion red blood cells, 295 million
platelets, and 7 million white blood cells.12 Identification
methods have evolved over the past two decades and now
focus on surface markers of intact cells. Although CTCs are a
heterogeneous population, they differ from normal circu-
lating peripheral blood cellse it is through these differences
that they are extracted from a blood sample.
Early methods for CTC identification utilized RT-PCR for
detection of tumor-specific antigens, assuming that these
antigens were not found in normal circulating blood.13e15
One of the first studies in head and neck cancer with re-
gard to CTCs looked at cytokeratin 20, an epithelial marker
that is expressed in many squamous carcinomas. In blood
samples of patients with oral squamous cell carcinoma,
there was an association between the presence of mRNA for
cytokeratin 20 and a reduced disease free survival and
increased lymph node metastases.16 However, a major lim-
itation to identification of CTCs utilizing this technique is the
lack of visual confirmation of the tumor cell. Although RT-
PCR is an efficient and reproducible technique, false posi-
tives from non-viable cellular material or from amplification
of non-specific genomic material cannot be excluded.
Most labs currently utilize techniques that can directly
visualize the cells of interest. Using positive selection
methods, epithelial surface antigens are targeted on thesurface of CTCs and “pulled out” of the blood sample.
EpCAM (epithelial cell adhesion molecule) is one of the
most commonly utilized markers and is the primary antigen
used in the only FDA-approved circulating tumor cell
detection equipment, CellSearch (Janssen Diagnostics, NJ,
USA). CellSearch utilizes a semi-automated process that
identifies EpCAM positive CTCs and “illuminates” them for
identification using fluorescently labeled cytokeratin 8, 18,
and 19. While this method is effective for identification of
EpCAM positive cells, it has become apparent in recent
years that metastatic cells display significant plasticity and
may lose EpCAM expression, thereby evading this detection
method.17e19 Konisberg and colleagues detected EpCAM
negative CTCs in metastatic breast cancer which were not
picked up by EpCAM dependent enrichment methods.17 This
raises the concern of false negatives if an EpCAM-only
method is utilized. Another well-studied marker for CTC
identification is cytokeratin (CK) and in the authors’ expe-
rience, this has proven to be more sensitive in detection of
CTCs. Within the cytokeratin family, CK 8, 18, 19, and 20
have been targeted the most in head and neck CTCs.
However, even cytokeratin may not be present on all
circulating tumor cells. The downregulation of EpCAM, and
to a lesser extent cytokeratin, is thought to be related to
epithelial to mesenchymal transition (EMT), whereby the
tumor cell loses its epithelial identity. Recent studies have
demonstrated this CTC heterogeneity: Weller et al noted
subpopulations of HNSCC CTCs with absence of CK, but
presence of N-cadherin (mesenchymal origin) and CD133
(stem-cell origin).20 Balsubramanian et al also detected
CTCs with presence of N-cadherin and Vimentin (mesen-
chymal origin), suggesting de-differentiation of a subset of
tumor cells that may elude standard identification tech-
niques.21 These findings highlight the importance of an
unbiased approach to CTC detection using multi-marker
testing. It also appears that the studies utilizing Cell-
Search identify a much lower absolute number of CTCs.
CellSearch appears to identify numbers in the single dig-
its22e24 more frequently than those utilizing other detec-
tion methods, which may reach thousands.25,26 Because
there is no normative value of CTCs in the bloodstream, it is
difficulty to draw conclusions as to which method is opti-
mum; however, it would make sense that methods utilizing
positive selection may “miss” CTCs because of low or non-
existent surface markers that are being targeted.
Contrary to the positive selection techniques above,
negative depletion techniques, such as the one utilized by
the authors, aim to remove as many “normal” blood cells as
possible in order to relatively increase the number of
circulating tumor cells in a sample. Using this method, an
average of 5.66 log10 enrichment is achieved, which allows
subsequent identification and characterization of CTCs
without relying on a particular biomarker. The tumor cells
can then undergo multi-marker staining; the presence of a
greater reduction in number of cells facilitates the manual
identification of the cells. In the first step of this process,
red blood cells (which make up the majority of circulating
blood cells) are removed by lysis. Leukocytes are then
labeled with anti-CD45 and removed by immunomagnetic
separation.27 With a majority of normal nucleated blood
cells removed, the remaining cells undergo nuclear staining
with DAPI (40,6-diamidino-2-phenylindole) and further
Circulating tumor cells in head and neck cancer 111immunocytochemical staining. Based on this information,
the definition of a circulating tumor cell is a nucleated
(DAPIþ) intact cell, negative for anti-CD45 and positive for
cytokeratin or other identified epithelial or mesenchymal
markers. Fig. 1 displays an example of confocal microscopy
and immunostaining characteristics of circulating tumor
cells using this approach.
Blood is typically drawn from of a peripheral venous
source, distant to the site of malignancy/intervention. In
an effort to reduce the chance of contamination, it has
been generally accepted, but not verified, that the first few
mL from the peripheral stick should be discarded. A ma-
jority of outcomes studies have examined CTCs measured
this way, although one study recently looked at measuring
CTCs from drain aspirates after extirpation for locally
advanced cN0 head and neck squamous cell carcinoma and
adenocarcinoma. They detected between 3 and 2094 CTCs/
ml in 64% patients using the CellSearch method, although
the clinical significance is still unknown.28 One of the lim-
itations of the immunocytochemical tests is the variability
in CTC recovery rates. As noted before, the rarity of these
cells in peripheral blood is one of the main challenges to
overcome. Hristozova and colleagues noted a mean recov-
ery rate of 69% in CTC spiked control samples using their
detection method.29 Reithdorf and colleagues examined
the inter and intra- assay variability as well as the stability
of the cell line over time using the CellSearch method.
Overall, they found reasonable reliability and reproduc-
ibility. Samples could be processed up to 72 h after blood
draw with good reliability. However, when looking at con-
trols spiked with a specified number of CTCs, the recovery
rates using CellSearch produced a mean of 80% (range:
30%e100%), indicating that there are limitations to
enumerating all of the known CTCs in a sample. They did
not, however, have a “negative” sample in the spiked
controls, demonstrating that CTCs were always found in the
sample even if the number was less than expected.30
The field of microfluidics has been proposed to present a
number of advantages in the recovery of CTCs and has been
evolving over a number of years. By way of a recentFig. 1 Multi-marker staining of circulating tumor cells in SCCHN
analysis. As defined, the cells are DAPIþ (40,6-diamidino-2-pheny
however, the first is also positive for mesenchymal marker, vimentmicrofluidic “chip assay” method, a volume of fluid is
applied to a very sensitive and specific “chip,” which acts
as a micro screen for detecting the CTC through DNA or RNA
aptamers. Early studies have shown this approach to be a
highly sensitive and specific tool.31 Using temperature
sensitive aptamers, it has been demonstrated that tumor
cells can be released in a viable state for further analysis. It
is also reusable, allowing for sensitivity >90% with repeated
use up to 6 times. The authors also report potential
improved cost with this method (owing to the reusability of
the equipment), although a direct analysis was not done.Clinical applications
With the knowledge of CTCs evolving in the field of head
and neck surgery, there is interest in determining what role
it plays in the treatment of head neck cancer. Detection of
CTCs in HNSCC range from 16% to 80% depending on the
detection method utilized.14,23e26,29,32e34 One of the most
promising ideas in circulating tumor cell detection in head
and neck squamous cell carcinoma is the correlation with
patient survival. Table 1 illustrates HNSCC CTC studies
examining survival and response to treatment. A majority
of studies have noted reduced disease free survival,25,26,34
reduced progression free survival, and overall survival.32
Follow up for these studies is notably short, ranging
19e36 months. Another study has noted no difference in
survival, although follow-up was only six months.22 A recent
meta-analysis examining circulating tumor cells in SCCHN
revealed that patients with CTCs had a significantly
increased risk of tumor progression, although presence of
CTCs did not appear to be related to T or N stage.37 A
predominating theory behind the differences seen in these
studies is the heterogeneity of CTCs, and that not every
tumor cell will go on to form a metastasis, or are related to
a metastasis. Efforts in the future should be targeted to
identifying the subset or subpopulation of cells that display
these aggressive properties.. A CTC (DIC) with corresponding immunocytochemical marker
lindole) and CD 45. Both are positive for cytokeratin (CK);
in.
Table 1 Summary of head and neck CTC studies.
Study N Study
design
Treatment
population
(stage)
Method of
detection
When CTCs
measured
Range
CTCs
Marker % With
CTCs
Mean
Follow-up,
months
Outcome
(þ)CTC:
() CTC
Other outcomes
Wirtshafter
et al
(2002)14
18 Prospective ⅠeⅣ Positive
Selection ICC
Before
treatment
0e3 EpCAM 44% N/A Outcomes not
examined
Partridge
et al
(2003)34
36 Prospective ⅠeⅣ Negative
Depletion
ICC and RT-PCR
Before, after
surgery
0e5 Pan-CK,
E48
50% 36 Reduced DFS Poor agreement
between RT-PCR
and ICC
Winter
et al
(2009)35
16 Prospective ⅠeⅣ RT-PCR Before, after
surgery
N/A EGFR,
CK,
ELF3,
Eph84
63% N/A No difference
Jatana
et al
(2010)26
48 Prospective ⅠeⅣ Negative
Depletion ICC
Before
treatment
0e3300 CK 71% 19 Reduced DFS
Hristozova
et al
(2011)29
42 Prospective LR advanced Flow cytometry
and RT-PCR
Before
treatment
0e4 EpCAM,
CK
43% N/A Assoc with
N2b disease
Decrease in
CTC with
chemoradiation
Nichols
et al
(2011)24
15 Prospective ⅢeⅣ CellSearch
(Positive
Selection ICC)
Before
treatment
0e2 EpCAM 40% N/A CTC presence
assoc. with lung
nodules >1 cm;
reduced survival
Buglione
et al
(2012)23
73 Prospective HNSCC and
SNUC (ⅠeⅣ)
CellSearch
(Positive
Selection ICC)
Before,
during,
after
treatment
0e43 EpCAM 15% 14 No difference Decrease in CTC
over treatment
correlated with
response; CTCs
presence trended
positively with
increasing stage
(NS)
Bozec
et al
(2013)22
49 Prospective ⅢeⅣ CellSearch
(Positive
Selection ICC)
N/A 0e5 EpCAM 16% 6 No difference
Hseih
et al
(2014)33
53 Prospective LR advanced,
recurrent,
metastatic
Negative
Depletion ICC
Before
treatment
N/A EpCAM 19% 10.5 PDPNþ/EpCAM
þ ratio >20%
prognostic factor
for DSM
Grisanti
et al
(2014)32
53 Prospective Recurrent/
Metastatic
CellSearch
(Positive
Selection
ICC)
Before,
during, after
treatment
0e43 EpCAM 26%
baseline;
41% at
any point
25 Reduced PFS
and OS
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Circulating tumor cells in head and neck cancer 113One biomarker of interest in head and neck CTCs is
podoplanin. Recent studies have examined podoplanin
(PDPN), a trans-membrane protein involved in lymphatic
formation, as a possible predictor of poor outcomes in head
and neck squamous cell carcinoma. Retrospective studies
have associated the degree of PDPN expression with
decreased survival in cutaneous squamous cell carcinoma38
and oral squamous cell carcinoma,39,40 although one study
suggests no association.41 All studies measured presence
and degree of expression of PDPN via immunohistochemical
techniques. It appears however, that PDPN may be lost
during de-differentiation in squamous carcinoma.41 There-
fore, lack of PDPN may not guarantee an improved survival.
Continuing this line of investigation, Hseih et al33 looked at
PDPN presence in CTCs of patient with locally advanced and
metastatic HNSCC and found that when the percentage of
an individual’s CTC count contained >20% PDPNþ/
EpCAM þ cells, there was a significant independent prog-
nostic factor for poor progression free and overall survival
at 12 months. Absolute presence of CTCs did not have an
effect on outcomes in this study, which supports the notion
of cell subtypes driving the outcomes.
Oliveira-Costa et al42 performed whole genome
sequencing of oral cavity SCCa patients using microarray
analysis in an effort to identify additional biomarkers that
portend a worse prognosis. They found that PDL-1 (pro-
grammed death ligand) expression was upregulated in the
primary tumor as tumor size increased. They then exam-
ined the association of circulating tumor cells with PDL-1
and disease specific survival in a separate cohort of pa-
tients. Interestingly, they found an improved short-term
survival benefit with the presence of cytoplasmic PDL-1
on CTCs. This was an unexpected finding given previous
literature suggesting association between PDL-1 and pro-
gression of disease. However, in recent years, other fields
have noted a similar finding between PDL-1 upregulation
and improved survival: in colorectal cancer,43 Merkel cell
carcinoma,44 and metastatic melanoma.45 Other pre-
liminary work has been done by measuring PDL-1 and its
receptor, PD-1, in oral cavity SCCa,46,47 but no additional
conclusions regarding outcomes could be surmised. With
PD-1 and PDL-1 being the target of Phase I and II therapies
in other fields of oncology, more research and knowledge
can be expected in the future.
EGFR has also been suggested as a possible CTC
biomarker for disease aggression in HNSCC, given its asso-
ciation with poor response to treatment in head and neck
cancer.48 Grisanti and colleagues measured CTCs in recur-
rent and metastatic HNSCC. They detected 26% and 41% of
CTCs at baseline and any point during treatment, respec-
tively.32 Within that study, 45% of the patients had EGFR
expression on CTCs. An interesting finding was that, in pa-
tients with multiple detected CTCs, only 25% of tumor cells
expressed EGFR, indicating evidence of CTC heterogeneity
within each tumor. No outcome analysis was done
comparing EGFR positivity in this study. In another study,
Tinhofer and colleagues also measured EGFR and its phos-
phorylated form, pEGFR in patients with locoregionally
advanced HNSCC.49 In their patient population, 100% of
sampled were þEGFR, and 55% were þpEGFR. When looking
at their two treatment groups, which included induction
chemotherapy followed by radiotherapy plus cetuximab vs.
114 K.P. McMullen et al.concurrent chemoradiotherapy, they found that the per-
centage of pEGFR expressing CTCs decreased more in the
Cextuximab group than in the concurrent group. In later
follow-ups, however, it appeared that the percentage of
pEGFR positive CTCs began to rise again in the Cetuximab
group. This is an expected finding given that Cetuximab
targets EGFR, and highlights the possibility of measuring
clinical response to targeted therapy with serial CTC
measurement.
The optimal time or interval to measure CTCs is not yet
clear. Many studies in head and neck measure CTCs at only
one point during an intervention (typically prior), although
studies have shown that CTCs fluctuate over the course of
treatment. Inhestern and colleagues recently published
their results examining changes in circulating tumor cells in
patients with oral and oropharyngeal SCCa.25 For all pa-
tients, this trial included induction chemotherapy followed
by stratification based on response with subsequent sur-
gery/postoperative therapy. They found that response to
induction chemotherapy was the most significant predictor
of overall survival. Patients who had a baseline CTC mea-
surement greater than the median baseline of the group
(3925 CTCs/ml) had significantly worse disease-free survival
than those with baseline numbers less than the median.
Overall survival was also lower in individuals whose
maximal CTC count at any point was higher than the median
maximal CTC count (5005 CTCs/ml). They also found that
CTCs fluctuated during the course of treatment: generally,
tumor cells decreased during chemotherapy, increased
after surgery, and decreased after radiation. Interestingly,
80% of patients were found to have CTCs at the beginning of
treatment, and this number increased to 97% at the
conclusion of treatment.
There is developing research with regards to treatment
related fluctuations of CTCs and whether this has a prog-
nostic effect. Kusakawa and colleagues detected cytoker-
atin using RT-PCR shortly after incisional biopsy of patients
with oral SCCa but not in their controls or patients who
underwent excisional biopsy.36 This was one of the first
suggestions in head and neck that direct manipulation
within a tumor may release CTCs in the vasculature. Similar
findings have been noted in primary lung cancer resection
as well.50
Jurati et al51 have done work with regard to in vivo
monitoring of CTCs in murine melanoma and breast cancer
models. Using fluorescence flow cytometry by monitoring a
single peripheral vein, they have identified dynamic
changes in the number of CTCs when the tumor is manip-
ulated. In the breast cancer model, there was no difference
in CTC dynamics when compared to controls with simple
pressure, analogous to mammography or pressure/manip-
ulation during surgery. In the punch biopsy group, the
number of CTCs increased 82% immediately and remained
elevated for five weeks after. On the contrary, complete
surgical resection (including negative margins) resulted in a
decrease in tumor cells, although tumor cells were again
detected at very low levels greater than 5 weeks after
surgery despite absence of any clinical recurrence. These
findings again suggest that tumor disruption may lead to an
increase in CTCs.
A central question from these studies is whether release
of CTCs by tumor manipulation affects prognosis. Thesecells are artificially released into the circulation. As a
result, it is unclear whether these “surgically-released”
tumor cells have acquired the phenotype capable of
causing metastasis. This makes sense clinically, as a tumor
may be actively manipulated during extirpation with no
consequence.
A chief limitation to research has been the heteroge-
neous detection methods by which laboratories detect
CTCs. A single, reproducible method of CTC identification
would standardize research at a multi-institutional level. As
discussed previously, CellSearch meets criteria for this
unifying test, but is not ideal given its reliance on EpCAM.
Although negative depletion and chip assay techniques are
unbiased, a standardized and marketable platform has not
been established yet. As methods for detecting CTCs are
further refined, we can expect an improved test in the
future that satisfies all the components above.
Conclusion
Detection and characterization of circulating tumor cells is
a promising tool for identification of early metastatic dis-
ease, response to treatment, and surveillance in head and
neck squamous cell carcinoma. It has been shown in mul-
tiple studies that presence of CTCs pre-treatment indicates
a decreased survival in the short term with long term
studies underway.
As detection methods evolve, it will be important to
identify which subpopulations of CTCs play a role in tumor
aggressiveness. As a result, an unbiased, multi-marker
approach to detection is necessary in order to identify
the heterogeneous population of cells. Standardization of
detection protocols would also aid in unifying the clinical
recommendations that can be made for influencing treat-
ment decisions.
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